Acarix: Comments on rights issue and coverage resumed - Redeye
Redeye resumes its coverage and comments on the outcome of Acarix’s rights issue. We will return early next week with a more elaborate research update.
ANNONS
Redeye resumes its coverage and comments on the outcome of Acarix’s rights issue. We will return early next week with a more elaborate research update.